 |
|
Continuous Subcutaneous Insulin Infusion
A Comprehensive Review of Insulin Pump Therapy
M. James Lenhard, MD;
Grafton D. Reeves, MD
Arch Intern Med. 2001;161:2293-2300.
ABSTRACT
A tremendous amount of data suggest that near-normal glycemic control
prevents or delays complications of diabetes, which has led to a dramatic
increase in continuous subcutaneous insulin infusion (CSII) or insulin pump
use. In this article, the data supporting CSII in type 1 diabetes is reviewed,
and the advantages and disadvantages of CSII are analyzed. In addition, CSII
use in specific situations is examined, including during childhood and pregnancy
and while exercising. The published articles suggest that CSII provides better
glycemic control than does conventional therapy and comparable to or slightly
better control than multiple daily injections. The use of CSII may be especially
indicated during pregnancy or for preconception care and for diabetes presenting
in childhood or adolescence.
INTRODUCTION
The Diabetes Control and Complications Trial (DCCT) demonstrated a dramatic
reduction in the frequency and severity of complications of diabetes mellitus
type 1 in adolescents and young adults by achieving and maintaining glucose
control in the near-normal range.1 Comparable
but less dramatic results were demonstrated in the UK Prospective Diabetes
Study for people with type 2 diabetes.2 These
studies established intensive management of diabetes as the standard of care,
which has rekindled an interest in external insulin infusion pumps, referred
to as continuous subcutaneous insulin infusion (CSII). The patients treated
with CSII in the DCCT demonstrated slightly better glycemic control than those
treated with multiple daily injections, and CSII therapy was well tolerated.3
Consequently, the popularity of CSII has increased dramatically. Approximately
50 000 to 70 000 adults in the United States are thought to be using
CSII, representing about 8% of the adult population with type 1 diabetes.4-5 In addition, the number of insulin
pump users is estimated to have doubled over the last 5 years.4
Despite this surge in popularity, a comprehensive review of CSII has not appeared
in the literature for many years, although brief reviews have been published
in textbooks.6-7 Continuous subcutaneous
insulin infusion seems to be the most physiologic method of delivering insulin
subcutaneously to achieve near-normal glycemic control. With patients and
their families demanding to use CSII, this review is an attempt to describe
the best uses, special considerations, and problems associated with CSII therapy.
DATA SOURCES
All articles found in MEDLINE from 1979 to 2000 that contained the words
"CSII" or "insulin pump" were read. There were 991 articles listed, although
some articles appeared on both lists. Review articles were included and differences
among conclusions explored. Both reviewers abstracted data independently.
PRINCIPLES AND BACKGROUND
Insulin pumps were introduced in the late 1970s. There was initial excitement
over this new technology,8-9 but
within a few years their popularity waned because their size, safety, and
efficacy became troublesome issues.10-11
Insulin pumps had a resurgence in popularity in late 1993 after the DCCT results
were published. The new pumps are smaller, more efficacious, and easier to
use. There are presently 3 manufacturers of insulin pumps in the United States:
Disetronic Medical Systems Inc (St Paul, Minn); MiniMed Technologies (Sylmar,
Calif); and Animas (Frasier, Pa). The new pumps are small, weighing around
400 g, and they all operate similarly. The insulin pump contains an insulin-filled
cartridge or a syringe connected to a catheter that is inserted into the subcutaneous
tissue (Figure 1). The pump continuously
delivers predetermined basal rates to meet nonprandial insulin requirements.
The devices allow programming of many different basal infusion rates, although
the average patient requires only 4 to 6 different rates (Figure 2). It also infuses a bolus to cover mealtime or snack time
insulin requirements.
|
|
|
|
Figure 1. A, Examples of 3 insulin infusion
pumps; B and C, 2 subcutaneous catheter infusion sets that may be used for
continuous subcutaneous insulin infusion.
|
|
|
|
|
|
|
Figure 2. A typical profile of basal insulin
infusion rates used in continuous subcutaneous insulin infusion. It is very
common for people with diabetes to require a higher basal infusion of insulin
in the predawn hours. Many people are more active in the late afternoon and
more sedentary after dinner, requiring downward and upward adjustments, respectively.
|
|
|
MISCONCEPTIONS
Therapy using CSII is not well understood by the public, patients with
diabetes, or even some health care providers. There is no surgery involved.
The subcutaneous catheter is manually inserted, typically in less than 5 minutes.
The pump is not an artificial pancreas. While patients who use CSII may sleep
later in the morning because their levels are better controlled for longer
duration, appropriate adjustments in the insulin infusion rates must be made.
They cannot ignore their calorie- and carbohydrate-restricted diets. The patient
needs to self-monitor blood glucose levels as much as if not more than patients
who rely on multiple daily injections (MDI). While there is good evidence
that CSII will provide better glycemic and metabolic control than MDI, with
fewer dangerous glycemic excursions, there is often a misconception that it
will completely eliminate episodes of severe hypoglycemia or hyperglycemia.
ADVANTAGES OF CSII
Glycemic Control
Intensive diabetes management with CSII provides better glycemic control
than does conventional management, which is usually defined as 2 or fewer
injections per day and 2 self-monitored blood glucose checks.12-13
It also provides as good and often better glycemic control than intensive
diabetes management with MDI.14-30
In addition to lowering the levels of glycosylated hemoglobin, CSII has been
shown to decrease glycemic variability31-32
and lower fasting glucose values.16, 29, 33-35
Hypoglycemia
Hypoglycemia is a serious risk associated with intensive therapy and
occurs with both CSII and MDI. Early studies suggested that the risk of hypoglycemia
with CSII was greater or similar to that of conventional diabetes management 36-37 and MDI.38-39
More recently, however, reports have suggested that severe hypoglycemia may
be reduced by CSII as much as 4-fold compared with MDI treatment40-41
with no reduction in glycemic control. This decrease in hypoglycemic events
has been accompanied by an increase in self-reported warning symptoms of hypoglycemia,
as well as by an increase in counterregulatory hormonal responses to hypoglycemia.42-43 Severe hypoglycemia has now become
an accepted indication for initiation of CSII therapy.
Other Metabolic Factors and Diabetes Complications
Intensive diabetes management with CSII improves glycemic control. The
improved control is associated with fewer diabetic and metabolic complications.
Treatment with CSII also improves or slows the progression of diabetic nephropathy,44-46 peripheral and autonomic
neuropathy,47-49
retinopathy,50-54
hypertriglyceridemia and hypoalphalipoproteinemia,55-56
and diabetic changes in transplanted kidneys.57
Lifestyle Flexibility
The improvement in lifestyle may be the most important reason to the
patient who chooses CSII. The ability to increase flexibility in moment-to-moment
living is the reason most frequently cited by individuals who have chosen
CSII.58 It allows the patient to modify insulin
availability hour by hour, which makes possible the performance of activities
that would otherwise be risky: skipping or delaying meals, sleeping late on
weekends, or engaging in vigorous exercise.59
This increased flexibility may be fueling the upsurge in patient demand for
CSII more than any other factor.
DISADVANTAGES OF CSII
As recently as 1990, some authorities asserted that "the use of CSII
is discouraged in routine clinical practice," suggesting instead that it be
limited to specific subsets of patients with type 1 diabetes.60
While earlier reports of increased and unexplained mortality among CSII users61 have largely been explained,11
there are several risks associated with CSII.
Diabetic Ketoacidosis
There is no subcutaneous depot of long-acting insulin with CSII. If
the flow of the regular, short-acting insulin is interrupted, ketonemia and
diabetic ketoacidosis can develop more rapidly and more frequently with CSII
than with other treatments.21, 36, 62
The interruption of insulin may be intentional, to allow patients to participate
in certain activities, or unintentional, caused by catheter occlusion, catheter
disinsertion, battery failure, depleted insulin supply, and other causes.63-65 Many times, the interruption
of insulin is a result of patient error and inadequate training, particularly
when patients do not take the emergency steps necessary in the event of unexplained
hyperglycemia.6 In experimental settings where
insulin delivery was intentionally interrupted, plasma-free insulin values
fell to very low levels (4-8 mU/L) within a 6-hour period, accompanied by
large increases in blood glucose, plasma 3- -hydroxybutyrate, and free
fatty acid values.66
Hypoglycemia
While hypoglycemia generally occurs less frequently with CSII than with
MDI, concern has been expressed about hypoglycemia resulting from unintentional
insulin delivery, or "pump runaway." While this event has occurred,67 it is exceedingly rare and, to our knowledge, has
not been found in the United States in the last 10 years. Technological advances
in the microprocessor components and insulin delivery alarms of the currently
marketed insulin pumps now make the occurrence of such an event extremely
unlikely.
Catheter Site Infection and Contact Dermatitis
The most common complication associated with CSII is infection at the
infusion site36, 67-68;
this is one of the most common causes listed for discontinuation of CSII.69 Most cases of infection have been bacterial, usually Staphylococcus or Streptococcus
species,70 although Rhizomucor cellulitis has been found.71 Presumably,
almost any pathogen could be a cause. There are conflicting reports as to
whether CSII users are chronic carriers of Staphylococcus.70, 72 Occasionally, the
infection may lead to cellulitis or abscess formation requiring surgical debridement.
The annual rate of catheter site infection has been estimated at 7.3 to 11.3
events per 100 years of patient follow-up.3
Additionally, occasional cases of contact dermatitis attributed to the components
of the infusion sets and tape have been described.73-74
On very rare occasions, the contact dermatitis persists despite changing the
type of tape and/or catheter, and is so severe that CSII must be discontinued.
Weight Gain
The most common metabolic adverse effect of improved glycemic control
is weight gain, largely attributable to reducing glycosuria. Participants
in the DCCT who used intensive management gained about 10 pounds (4.5 kg)
more than the conventional treatment group,1
although there was no difference in the weight gained between patients using
CSII and those using MDI.3
Cost
The insulin pump and the supplies needed to begin therapy average about
$5000. The infusion set and catheters must be purchased regularly for as long
as CSII is used, at a yearly cost of approximately $1500. Most insurance companies,
including Medicare and Medicaid, cover the cost of CSII treatment after medical
approval. We are not aware of any detailed studies of the cost-benefit analysis
of CSII.
Prevention of Disadvantages
To minimize the risk of ketoacidosis, patients must check their blood
glucose levels at least 4 times a day to prevent the development of severe
diabetic ketoacidosis. Frequent self-monitoring of blood glucose levels will
also allow for early recognition of hypoglycemia. A change of catheter site
every 2 to 3 days will minimize the risk for developing skin infections. The
application of a local antibiotic ointment to mild skin infections will usually
cure them, and creams with aloe, vitamin E, or corticosteroids may be helpful
for contact dermatitis. Weight gain does not have to occur with CSII. Exercise
and close attention to caloric intake can result in weight maintenance and,
if necessary, weight reduction.
SPECIAL CONSIDERATIONS WITH CSII THERAPY
Choice of Insulin for CSII
Phosphate-buffered insulin demonstrates a decreased incidence of catheter
obstruction, and therefore is the preferred insulin for CSII.75
There are currently 2 insulin preparations available that contain a phosphate
buffer. Velosulin (Novo Nordisk, Princeton, NJ) is buffered regular insulin,
and lispro insulin (Lilly, Indianapolis, Ind) is an insulin analogue modified
to provide very fast action. While only Velosulin has a Food and Drug Administration
indication for CSII, lispro insulin has some clear advantages: lispro CSII
has resulted in less severe and fewer cases of hypoglycemia and better glycemic
control than Velosulin CSII.75-78
However, since lispro is more rapidly absorbed, there is a concern that the
interruption of lispro insulin infusion may lead to more rapid metabolic deterioration
than an interrupted infusion with buffered regular insulin. Consensus is lacking.
One study showed no temporal difference.79
Another study showed that with lispro metabolic deterioration occurred 1.5
to 2 hours earlier and was associated with a larger decrease in blood pH.80 Thus, CSII with lispro insulin seems to provide better
glycemic control and fewer and less severe instances of hypoglycemia than
CSII with buffered regular insulin, although diabetic ketoacidosis may develop
more rapidly.
CSII Use in Children and Adolescents
In contrast to the adult population with type 1 diabetes, there is scarce
data on the use of CSII in the adolescent and childhood populations (especially
childhood). The literature includes few studies, all very limited in scope;
none are randomized, and most involve adolescents. Most of the studies are
small, usually 25 or fewer subjects, and short in duration, usually 12 months
or less.81-90
In addition to nonrandomization, a limited number of subjects, and a relatively
short duration, the 3 CSII studies in the childhood diabetic population have
other major limitations. Two involve only toddlers,91-92
and the others involve only children with newly diagnosed diabetes.93-94
The results of the few studies in the adolescent and childhood diabetes
population are contradictory. Most of the studies, especially the more recent
ones, demonstrate that insulin pump therapy provides as good or better metabolic
and glycemic control than MDI and that it is as well or better tolerated.3, 81-86
Earlier studies, however, demonstrated that it did not provide better control
and was not well tolerated.87-88
Recent studies demonstrate that CSII is associated with lower or comparable
rates of complications such as hypoglycemia, ketoacidosis, and weight gain
than are MDI,85, 89-90,95
while earlier studies demonstrated more complications.87-88
Notwithstanding the scarcity of information and some variance in the findings
on the safety and efficacy of CSII in the pediatric diabetes population, children
and adolescents with diabetes and their parents are demanding to use the pump
because they perceive it to be the safest, easiest, and the most physiologic
method of delivering insulin subcutaneously to achieve near-normal glycemic
control.
CSII Use During Pregnancy
The association between excessive maternal hyperglycemia in women with
type 1 diabetes and the risk of fetal anomalies is well accepted.96-97 In addition to striving for preconception
euglycemia, euglycemic or near euglycemic control should be the goal throughout
pregnancy. Hypoglycemia increases during the first trimester of pregnancy.
This may be due in part to attempts at improved metabolic control, the passive
diffusion of glucose across the placenta, and alterations in the counterregulatory
responses of epinephrine, growth hormone, and glucagon.98
Kimmerle et al99 reported rates of severe hypoglycemia,
defined as coma, seizure, or incapacitation requiring the help of others,
to be as high as 41% in pregnant women with diabetes. With the advantages
of CSII in decreasing hypoglycemia and improving glycemic variability, it
is logical to assume that CSII would be beneficial for pregnant women with
diabetes. As with early studies of CSII efficacy for glycemic control in nonpregnant
patients, some of the earlier studies of CSII during pregnancy demonstrated
no significant improvement in glycemic control, perinatal morbidity, or length
of hospitalization.100 Subsequent studies,
however, suggest that CSII is superior to conventional therapy97, 101
and at least comparable to MDI102-104
in achieving metabolic goals in pregnancy. Several aspects of CSII suggest
that even if glycemic control is only comparable to MDI, pregnant women may
prefer CSII because of its several advantages. These include increased ease
of treating morning sickness and hyperemesis gravidarum, reductions in glycemic
excursions and hypoglycemia, ease of treating the dawn phenomenon that increases
during pregnancy, and improved management in the postpartum period when insulin
requirements may fluctuate.105 Three studies
have found comparable results for pregnant women with type 2 or gestational
diabetes,104-106
although this area has not been well studied.
CSII Use for Type 2 Diabetes
The data on CSII therapy in type 2 diabetes is rather scarce compared
with data for treating type 1 diabetes, although the enthusiasm for implementing
CSII with type 2 diabetes has increased.107
Several short-term trials have demonstrated improvement in glycemic control
at 6 months,108-109 improved -cell
function and first-phase insulin secretion,110-111
and improvement in the altered metabolic milieu associated with type 2 diabetes.112-113 There is only 1 randomized trial
comparing CSII with conventional insulin therapy.114
In this 4-month trial involving 20 subjects, CSII achieved superior glycemic
control, with comparable insulin doses and similar amounts of weight gain.
Ultimately, CSII may prove to be of significant benefit to patients with type
2 diabetes, but the paucity of data makes it impossible to draw any conclusions
at present. The many publications detailing the successful use of the experimental
implantable insulin pump in type 2 diabetes gives hope that these results
can be extended to CSII.115
CSII and Exercise
Habitual physical activity has significant benefit to the patient with
diabetes, and CSII may make it easier for the patient to maintain glycemic
parameters acutely during exercise because of its ability to readily alter
the rate of insulin delivery.116 Although CSII
has not always led to significant improvement in postexercise hyperglycemia,117 insulin sensitivity and aerobic exercise capacity
have been shown to improve with CSII.118-119
Several studies have suggested that CSII may be superior to conventional insulin
therapy in improving cardiac function in subjects with cardiac autonomic neuropathy.119-120 And while regular exercise is certainly
to be encouraged, adequate training of the CSII user is essential to allow
safe changes in the basal infusion rate and to avoid disrupting the catheter
site during brisk physical activity.121
Psychological and Social Implications of CSII
The use of CSII may evoke psychological issues to a greater degree than
conventional diabetes therapy.122 An emotional
and psychosocial assessment is necessary prior to initiating CSII to prevent
discontinuation and ensure proper use of the pump.
Several aspects of CSII are unique, and therefore may present barriers
to successful glycemic control. Since the pump is visible to others, some
patients express difficulty with body image and their self-perceived attractiveness.123 Other people feel inconvenienced explaining CSII
to others and consider it an invasion of their privacy.124
Although CSII may help provide exceptional metabolic control, this mechanical
dependency may invoke feelings of vulnerability and fear of device failure.122 Patient and family education prior to initiation
of CSII helps to minimize this.122 Patient
selection is vital to patient tolerance of CSII. It is not always possible
to predict whether CSII will be successful.95
While some studies have shown CSII to be associated with significantly less
anxiety and depression and improved family social dynamics,125
other studies have suggested that these benefits are most notable in patients
who asked to remain on CSII after completion of the study.126-127
In effect, these studies self-selected those patients who were likely to express
the greatest satisfaction and least psychological discomfort with CSII. There
are few data on the psychological effect of CSII in children and adolescents,
with studies showing both an improved sense of control over their life for
some patients128 and an increase in anxiety
for others.129
Patient Selection and Implementation of CSII
Several excellent texts and articles on the strategies and procedures
of initiating CSII have been published and provide a detailed "how to" guide
for the health care practitioner.7, 130-135
Beginning CSII involves more than merely changing the method of insulin delivery.
Patients should participate in a formal educational program. A dietitian should
instruct the patient in proper meal planning and carbohydrate counting, whereby
the patient calculates the quantity of insulin to take at each meal based
on the amount of carbohydrates to be consumed. A diabetes educator should
instruct the patient in insulin pump management. And a psychologist and/or
social worker should assess motivation, cognitive and problem-solving skills,
maturity level, financial stability, and social support systems. It may be
difficult to successfully implement CSII without the assistance of ancillary
health care providers and a team approach. The successful implementation of
CSII may be as dependent on a motivated, flexible, and skilled health care
team as it is on the patient.
There are no universally applicable criteria for determining which patients
will do well on CSII. Table 1
lists some characteristics that may help determine which patients will be
successful. The current model is that the motivated, relatively stable patient
is the best candidate for CSII. A different school of thought, however, holds
that the patient with poorly controlled diabetes who may, in addition, not
possess the highest level of motivation, cognitive skills, or social support
may benefit to an even greater degree than the more enfranchised patient.
There is currently no data to support this opinion, but relevant research
is being conducted.
|
|
|
|
Characteristics to Consider When Evaluating a Potential CSII User*
|
|
|
SUMMARY
Continuous subcutaneous insulin infusion has proven to be extremely
effective in treating type 1 diabetes. It provides glycemic control superior
to that of conventional therapy and comparable or slightly superior to MDI.
It also decreases the frequency and/or severity of hypoglycemic reactions
and increases lifestyle flexibility. With good compliance and proper attention
to details, the disadvantages and risks of CSII can be minimized.
Some specific patient situations may be especially attractive for the
use of CSII, including pregnancy or preconception care and diabetes presenting
in childhood or adolescence. For the successful use of CSII, a skilled and
motivated health care delivery team is required, and a thorough evaluation
and training of the CSII candidate is necessary prior to implementation. There
is also a need for ongoing close contact between the pump user and the health
care team.
AUTHOR INFORMATION
Accepted for publication March 29, 2001.
We thank Zoe Meyers of Disetronic Medical Systems Inc (St Paul, Minn),
and the librarians at the Christiana Care Medical Library, Wilmington, Del,
especially Joan Smith, for assistance with the literature search.
The photographs were expertly taken at the Medical Photography section
at Christiana Hospital.
Corresponding author and reprints: M. James Lenhard, MD, Diabetes
and Metabolic Diseases Center, Section of Endocrinology, Christiana Care Health
Services, 700 Lea Blvd, Suite 300, Wilmington, DE 19802 (e-mail: JLenhard{at}ChristianaCare.org).
From the Diabetes and Metabolic Diseases Center, Section of Endocrinology,
Christiana Care Health Services (Dr Lenhard), and the Division of Pediatric
Endocrinology, DuPont Hospital for Children (Dr Reeves), Wilmington, Del;
and Jefferson Medical College, Thomas Jefferson University, Philadelphia,
Pa (Drs Lenhard and Reeves).
REFERENCES
| |
1. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): the effect of intensive
treatment of diabetes on the development and progression of long-term complications
in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
FREE FULL TEXT
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients with type
2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
FULL TEXT
|
ISI
| PUBMED
3. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications
Trial. Diabetes Care. 1995;18:361-376.
ABSTRACT
4. Boaz-Christy K. Up and pumping: chart your way to better control. Diabetes Interview. March 1999:30.
5. Brody JE. Small, convenient and flexible, insulin pumps catch on. New York Times. August 10, 1999; Personal Health section.
6. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am. 1997;26:599-610.
FULL TEXT
|
ISI
| PUBMED
7. Strowig S, Raskin P. Intensive management of insulin-dependent diabetes mellitus. In: Porte D, Sherwin RS, eds. Ellenberg's and Rifkin's
Diabetes Mellitus. 5th ed. Stamford, Conn: Appleton & Lange; 1997:709-733.
8. Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving
normoglycaemia. BMJ. 1978;1:204-207.
9. Tamborlane WV, Sherwin RS, Genet M, et al. Normalization of plasma glucose in juvenile diabetics by subcutaneous
administration of insulin with a portable infusion pump. N Engl J Med. 1979;300:573-578.
ABSTRACT
10. Unger RH. Meticulous control of diabetes: benefits, risks and precautions. Diabetes. 1979;31:479-483.
ISI
| PUBMED
11. Teutsch SM, Herman WH, Dwyer DM, et al. Mortality among diabetic patients using continuous subcutaneous insulin-infusion
pumps. N Engl J Med. 1984;310:361-368.
ABSTRACT
12. Tamborlane WV, Sherwin RS, Genel M, et al. Outpatient treatment of juvenile-onset diabetes with a preprogrammed
portable subcutaneous insulin infusion system. Am J Med. 1980;68:190-196.
FULL TEXT
|
ISI
| PUBMED
13. Pickup JC, White MC, Keen H, et al. Long-term continuous subcutaneous insulin infusion in diabetics at
home. Lancet. 1979;2:870-873.
ISI
| PUBMED
14. Kobayashi T, Sawano S, Itoh T, et al. The pharmacokinetics of insulin after continuous subcutaneous infusion
or bolus subcutaneous injection in diabetic patients. Diabetes. 1983;32:331-336.
ABSTRACT
15. Rizza RA, O'Brien PC, Service FJ. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations
after chronic ultralente administration in patients with IDDM. Diabetes Care. 1986;9:120-123.
ABSTRACT
16. Schiffrin A, Belmonte MM. Comparison between continuous subcutaneous insulin infusion and multiple
injections of insulin: a one-year prospective study. Diabetes. 1982;31:255-264.
ABSTRACT
17. Leichter SB, Schreiner ME, Reynolds LR, et al. Long-term follow-up of diabetic patients using insulin infusion pumps:
considerations for future clinical application. Arch Intern Med. 1985;145:1409-1412.
FREE FULL TEXT
18. Deeb LC, Williams PE. Surveillance in Florida of continuous subcutaneous insulin infusion
use in cohort. Diabetes Care. 1986;9:591-595.
ABSTRACT
19. Simonson DC, Tamborlane WV, Sherwin RS, et al. Improved insulin sensitivity in patients with type I diabetes mellitus
after CSII. Diabetes. 1985;34 Suppl 3:80-86.
20. The Kroc Collaborative Study Group. Collaborative studies of the effects of continuous subcutaneous insulin
infusion in insulin-dependent diabetes mellitus: conclusions. Diabetes. 1985;34 (suppl 3):87-89.
21. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and
albuminuria: a preliminary multicenter trial. N Engl J Med. 1984;311:365-372.
ABSTRACT
22. Lauritzen T, Frost-Larsen K, Larsen H-W, et al. Two-year experience with continuous subcutaneous insulin infusion in
relation to retinopathy and neuropathy. Diabetes. 1985;34(suppl 3):74-79.
23. Haakens K, Hanssen KF, Dahl-Jorgensen K, et al. Continuous subcutaneous insulin infusion (CSII), multiple injections
(MI), and conventional insulin therapy (CT) in self-selecting insulin-dependent
diabetic patients: a comparison of metabolic control, acute complications
and patient preferences. J Intern Med. 1990;228:457-464.
ISI
| PUBMED
24. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early
diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed). 1986;293:1195-1199.
25. Schiffrin A, Colle E, Belmonte M. Improved control in diabetes with continuous subcutaneous insulin infusion. Diabetes Care. 1980;3:643-649.
ABSTRACT
26. Helve E, Koivisto VA, Lehtonen A, et al. A cross-over comparison of continuous insulin infusion and conventional
injection treatment of type 1 diabetes. Acta Med Scand. 1987;221:385-393.
ISI
| PUBMED
27. Rizza RA. Treatment options for insulin-dependent diabetes mellitus: a comparison
of the artificial endocrine pancreas, continuous subcutaneous insulin infusion,
and multiple daily injections. Mayo Clin Proc. 1986;61:796-805.
ISI
| PUBMED
28. Mecklenburg RS, Benson EA, Benson JW Jr, et al. Long-term metabolic control with insulin pump therapy: report of experience
with 127 patients. N Engl J Med. 1985;313:465-468.
ABSTRACT
29. Reeves ML, Seigler DE, Ryan EA, et al. Glycemic control in insulin-dependent diabetes mellitus: comparison
of outpatient intensified conventional therapy with continuous subcutaneous
insulin infusion. Am J Med. 1982;72:673-680.
FULL TEXT
|
ISI
| PUBMED
30. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications
Trial. Diabetes Care. 1995;18:361-377.
31. Bischof F, Meterhoff C, Pfeiffer EF. Quality control of intensified insulin therapy: HbA1 versus
blood glucose. Horm Metab Res. 1994;26:574-578.
ISI
| PUBMED
32. Lauritzen T, Pramming S, Deckert T, et al. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24:326-329.
ISI
| PUBMED
33. Koivisto VA, Yki-Jarvinen H, Karonen S-L, et al. Pathogenesis and prevention of the dawn phenomenon in diabetic patients
treated with CSII. Diabetes. 1986;35:78-82.
ABSTRACT
34. Haakens K, Hanssen KF, Dahl-Jorgensen K, et al. Early morning glycaemia and the metabolic consequences of delaying
breakfast/morning insulin: a comparison of continuous subcutaneous insulin
infusion and multiple injection therapy with human isophane or human ultralente
insulin at bedtime in insulin-dependent diabetics. Scand J Clin Lab Invest. 1989;49:653-659.
ISI
| PUBMED
35. Guerci B, Meyer L, Delbachian I, et al. Blood glucose control on Sunday in IDDM patients:intensified conventional
insulin therapy versus continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 1998;40:175-180.
FULL TEXT
|
ISI
| PUBMED
36. Mecklenburg RS, Benson EA, Benson JW Jr, et al. Acute complications associated with insulin pump therapy: report of
experience with 161 patients. JAMA. 1984;252:3265-3269.
FREE FULL TEXT
37. Muhlhauser I, Berger M, Sonnenberg G, et al. Incidence and management of severe hypoglycemia in 434 adults with
insulin-dependent diabetes mellitus. Diabetes Care. 1985;8:268-273.
ABSTRACT
38. Arias P, Kerner W, Zier H, et al. Incidence of hypoglycemic episodes in diabetic patients under continuous
subcutaneous insulin infusion and intensified conventional insulin treatment:
assessment by means of semiambulatory 24-hour continuous blood glucose monitoring. Diabetes Care. 1985;8:134-140.
ABSTRACT
39. White NH, Skor DA, Cryer PE, et al. Identification of type I diabetic patients at increased risk for hypoglycemia
during intensive therapy. N Engl J Med. 1983;308:485-491.
ABSTRACT
40. Bode BW, Steed DR, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous
insulin infusion in type 1 diabetes. Diabetes Care. 1996;19:324-327.
ABSTRACT
41. Haardt MJ, Berne C, Dorange C, et al. Efficacy and indications of CSII revisited: the Hotel Dieu cohort. Diabetic Med. 1997;14:407-408.
42. Del Rio G, Baldini A, Carani C, et al. Adrenomedullary hyperactivity in type 1 diabetic patients before and
during continuous subcutaneous insulin treatment. J Clin Endocrinol Metab. 1989;68:555-559.
FREE FULL TEXT
43. Kanc K, Janssen MJ, Keulen ETP, et al. Substitution of night-time continuous subcutaneous insulin infusion
therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory
hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia. 1998;41:322-329.
FULL TEXT
|
ISI
| PUBMED
44. Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Effect of 2 years of strict metabolic control on progression of incipient
nephropathy in insulin-dependent diabetes. Lancet. 1986;2:1300-1304.
FULL TEXT
| PUBMED
45. Deckert T, Lauritzen T, Parving H-H, et al. Effect of two years of strict metabolic control on kidney function
in long-term insulin-dependent diabetics. Diabet Nephropathy. 1984;3:6-10.
46. Dahl-Jorgensen K, Bjoro T, Kierulf P, et al. Long-term glycemic control and kidney function in insulin-dependent
diabetes mellitus. Kidney Int. 1992;41:920-923.
ISI
| PUBMED
47. Boulton AJM, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful
diabetic neuropathy. Diabetes Care. 1982;5:386-390.
ABSTRACT
48. Jakobsen J, Christiansen JS, Kristoffersen I, et al. Autonomic and somatosensory nerve function after 2 years of continuous
subcutaneous insulin infusion in type 1 diabetes. Diabetes. 1988;37:452-455.
ABSTRACT
49. Kronert K, Hulser J, Luft D, et al. Effects of continuous subcutaneous insulin infusion and intensified
conventional therapy on peripheral and autonomic nerve function. J Clin Endocrinol Metab. 1987;64:1219-1223.
FREE FULL TEXT
50. Helve E, Laatikainene L, Merenmies L, et al. Continuous insulin infusion therapy and retinopathy in patients with
type I diabetes. Acta Endocrinol (Copenh). 1987;115:313-319.
51. Bibergeil H, Huttl I, Felsing W, et al. 36 Months continuous subcutaneous insulin infusion (CSII) in insulin
dependent diabetes (IDDM)—influence on early stages of retinopathy,
nephropathy and neuropathy: psychological analysis. Exp Clin Endocrinol. 1987;90:51-61.
ISI
| PUBMED
52. White NH, Waltman SR, Krupin T, et al. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent
diabetes after five to nine months of improved metabolic control. Diabetes. 1982;31:80-85.
ABSTRACT
53. Selam JL, Millet P, Saluski S, et al. Beneficial effect of glycaemic improvement in non-ischaemic forms of
diabetic retinopathy: a 3-year follow-up. Diabet Med. 1986;3:60-64.
ISI
| PUBMED
54. Shimizu H, Shimomura Y, Takahashi M, et al. Enteral hyperalimentation with continuous subcutaneous insulin infusion
improved severe diarrhea in poorly controlled diabetic patient. JPEN J Parenter Enteral Nutr. 1991;15:181-183.
FREE FULL TEXT
55. Falko JM, O'Dorisio TM, Cataland S. Improvement of high-density lipoprotein-cholesterol levels: ambulatory
type I diabetics treated with the subcutaneous insulin pump. JAMA. 1982;247:37-39.
FREE FULL TEXT
56. Lawson P, Trayner I, Rosenstock J, et al. The effect of continuous subcutaneous insulin infusion on serum lipids. Diabete Metab. 1984;10:239-244.
ISI
| PUBMED
57. Schmitz O, Schwartz Sorensen S, Alberti KGMM, et al. Metabolic control in newly kidney transplanted insulin-dependent diabetics:
improvement by insulin pump treatment (CSII). J Diabet Complications. 1987;1:81-86.
PUBMED
58. American Association of Diabetes Educators. Position statement: education for continuous subcutaneous insulin infusion
pump users. Diabetes Educ. 1986;13:10.
59. Marcus AO. Patient selection for insulin pump therapy. Pract Diabetol. November 1992:12-18.
60. Selam J-L, Charles MA. Devices for insulin administration. Diabetes Care. 1990;13:955-979.
ABSTRACT
61. Deaths among patients using continuous subcutaneous insulin infusion
pumps. MMWR Morb Mortal Wkly Rep. 1982;31:80-82.
PUBMED
62. Home PD, Marshall SM. Problems and safety of continuous subcutaneous insulin infusion. Diabet Med. 1984;1:41-44.
PUBMED
63. Mecklenburg RS, Guinn TS, Sannar CA, et al. Malfunction of continuous subcutaneous insulin infusion systems: a
one-year prospective study of 127 patients. Diabetes Care. 1986;9:351-355.
ABSTRACT
64. Peden NR, Braaten JT, McKendry JBR. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous
insulin infusion. Diabetes Care. 1984;7:1-5.
ABSTRACT
65. Castillo MJ, Scheen AJ, Lefebvre PJ. Treatment with insulin infusion pumps and ketoacidotic episodes: from
physiology to troubleshooting. Diabetes Metab Rev. 1995;11:161-177.
ISI
| PUBMED
66. Castillo MJ, Scheen AJ, Lefebvre PJ. The degree/rapidity of the metabolic deterioration following interruption
of a subcutaneous insulin infusion is influenced by the prevailing blood glucose
level. J Clin Endocrinol Metab. 1996;81:1975-1978.
ABSTRACT
67. Midthjell K, Kapelrud H, Bjornerud A, et al. Severe or life-threatening hypoglycemia in insulin pump treatment. Diabetes Care. 1994;17:1235-1236.
ISI
| PUBMED
68. Pietri A, Raskin P. Cutaneous complications of chronic continuous subcutaneous insulin
infusion therapy. Diabetes Care. 1981;4:624-626.
ABSTRACT
69. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of subcutaneous insulin-infusion
therapy. Diabetes Care. 1988;11:46-51.
ABSTRACT
70. Chantelau E, Lange G, Sonnenberg GE, et al. Acute cutaneous complications and catheter needle colonization during
insulin-pump treatment. Diabetes Care. 1987;10:478-482.
ABSTRACT
71. Wickline CL, Cornitius TG, Butler T. Cellulitus caused by Rhizomucor pusillus in
a diabetic patient receiving continuous insulin infusion pump therapy. South Med J. 1989;82:1432-1434.
FULL TEXT
|
ISI
| PUBMED
72. Van Faassen, Razenberg PPA, Simoons-Smit AM, et al. Carriage of Staphylococcus aureus and inflamed
infusion sites with insulin-pump therapy. Diabetes Care. 1989;12:153-155.
ABSTRACT
73. Van Den Hove J, Jacobs M-C, Tennstedt D, et al. Allergic contact dermatitis from acrylates in insulin pump infusion
sets. Contact Dermatitis. 1996;35:108.
FULL TEXT
|
ISI
| PUBMED
74. Corazza M, Maranini C, Alleotti A, et al. Nickel contact dermatitis due to the needle of an insulin pump, confirmed
by microanalysis. Contact Dermatitis. 1998;39:144.
ISI
| PUBMED
75. Mecklenburg RS, Guinn TS. Complications of insulin pump therapy: the effect of insulin preparation. Diabetes Care. 1985;8:367-370.
ABSTRACT
76. Schmaub S, Konig A, Landgraf R. Human insulin analogue [LYS(B28),PRO(B29)]: the ideal pump insulin? Diabet Med. 1998;15:247-249.
FULL TEXT
|
ISI
| PUBMED
77. Zinman B, Tildesley H, Chiasson J-L, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440-443.
ABSTRACT
78. Melki V, Renard E, Lassman-Vague V, et al. Improvement of HbA1c and blood glucose stability in IDDM
patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21:977-982.
ABSTRACT
79. Attia N, Jones TW, Holcombe J, et al. Comparison of human regular and lispro insulins after interruption
of continuous subcutaneous insulin infusion and in the treatment of acutely
decompensated IDDM. Diabetes Care. 1998;21:817-821.
ABSTRACT
80. Reichel A, Rietzsch H, Kohler HJ, et al. Cessation of insulin infusion at night-time during CSII-therapy: comparison
of regular human insulin and insulin lispro. Exp Clin Endocrinol Diabetes. 1998;106:168-172.
ISI
| PUBMED
81. Rudolf MC, Ahern J, Genel M, et al. Optimal insulin delivery in adolescents with diabetes: impact of intensive
treatment or psychosocial adjustment. Diabetes Care. 1982;5(suppl 1):53-57.
82. Schiffrin AD, Desrosiers M, Aleyossine H, et al. Intensified insulin therapy in the type 1 diabetic adolescent: a controlled
trial. Diabetes Care. 1984;7:107-113.
ABSTRACT
83. Tamborlane WV, Batas SE, Rudolf MC, et al. Comparison of continuous subcutaneous insulin infusion versus multiple
daily injections in adolescents with insulin-dependent diabetes. Adv Diabetologia. 1989;2(suppl 1):24-27.
84. De Beaufort CE, Bruning GJ. Continuous subcutaneous insulin infusion in children. Diabet Med. 1987;4:103-108.
ISI
| PUBMED
85. Oesterle A, Boland E, Yu C, et al. CSII: a new way to achieve strict metabolic control and lower the risk
of severe hypoglycemia in adolescents [abstract]. Diabetes. 1998;21(suppl 1):1320A.
86. Boland E, Ahern J, Grey M. A primer on the use of insulin pumps in adolescents. Diabetes Educ. 1998;24:78-86.
87. Knight G, Boulton AJM, Ward JD. Experience of subcutaneous insulin infusion in the outpatient management
of diabetic teenagers. Diabet Med. 1986;3:82-84.
ISI
| PUBMED
88. Becker D, Kernesky K, Transue D, et al. Continuous subcutaneous insulin infusion (CSII) in adolescents with
IDDM [abstract]. Int Study Group Diabetes Child Adolesc Bull. 1984;11:10.
89. Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents
with poorly controlled type 1 diabetes. Diabetes Res Clin Pract. 1995;27:199-204.
FULL TEXT
|
ISI
| PUBMED
90. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of
severe hypoglycemia, improve metabolic control, and enhance coping in adolescents
with type 1 diabetes. Diabetes Care. 1999;22:1779-1784.
FREE FULL TEXT
91. Bougneres PF, Landier F, Lammel C, et al. Insulin pump therapy in young children with type 1 diabetes. J Pediatr. 1984;105:212-217.
FULL TEXT
|
ISI
| PUBMED
92. Tubiana-Rufi N, de Lonlay P, Bloch J, et al. Dispartition des accidents hypoglycemiques severes chez le tres jeune
enfant diabetique traite par pompe sours-cutanee. Arch Pediatr. 1996;3:969-976.
FULL TEXT
|
ISI
| PUBMED
93. de Beaufort CE, Bruining GJ, Aarsan RSR, et al. Does subcutaneous insulin infusion (CSII) prolong the remission phase
of insulin-dependent diabetic children? Neth J Med. 1985;28:53-54.
94. Beaufort CE. Continuous Subcutaneous Insulin Infusion in Newly
Diagnosed Diabetic Children. Rotterdam, the Netherlands: Mo Thesis; 1986.
95. Bougneres PF, Landier F, Lammel C, et al. Insulin pump therapy in young children with type 1 diabetes. J Pediatr. 1984;105:212-217.
96. Kitzmiller JL, Cloherty JP, Younger MD, et al. Diabetic pregnancy and perinatal morbidity. Am J Obstet Gynecol. 1978;131:560-580.
ISI
| PUBMED
97. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes: glycemic control prevents congenital
anomalies. JAMA. 1991;265:731-736.
FREE FULL TEXT
98. Diamond MP, Reece EA, Caprio S, et al. Impairment of counterregulatory hormone response to hypoglycemia in
pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol. 1992;166:70-77.
ISI
| PUBMED
99. Kimmerle R, Heinemann L, Delecki A, et al. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies
of type 1 diabetic women. Diabetes Care. 1992;15:1034-1037.
ABSTRACT
100. Leveno KJ, Fotunato SJ, Raskin P, et al. Continuous subcutaneous insulin infusion during pregnancy. Diabetes Res Clin Pract. 1988;4:257-268.
FULL TEXT
|
ISI
| PUBMED
101. Jensen BM, Kuhl C, Molsted-Pedersen L, et al. Preconceptional treatment with insulin infusion pumps in insulin-dependent
diabetic women with particular reference to prevention of congenital malformations. Acta Endocrinol Suppl (Copenh). 1986;277:81-85.
102. Potter JM, Reckless PD, Cullen DR. The effect of continuous subcutaneous insulin infusion and conventional
insulin regimes on 24-hour variations of blood glucose and intermediary metabolites
in the third trimester of diabetic pregnancy. Diabetologia. 1981;21:534-539.
ISI
| PUBMED
103. Burkart W, Hanker JP, Schneider HPG. Complications and fetal outcome in diabetic pregnancy. Gynecol Obstet Invest. 1988;26:104-112.
FULL TEXT
|
ISI
| PUBMED
104. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional
insulin therapy in type I and type II diabetic pregnancy. Diabete Metab. 1986;12:121-129.
ISI
| PUBMED
105. Jornsay DL. Continuous subcutaneous insulin infusion (CSII) therapy during pregnancy. Diabetes Spectrum. 1998;11:26-32.
106. Caruso A, Lanzone A, Bianchi V, et al. Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic
patients. Prenat Diagn. 1987;7:41-50.
ISI
| PUBMED
107. Patten BC, Lenhard MJ. Type 2 diabetes and pumps: out on a limb? Diabetes Forecast. 1999;52:48-52.
108. Della Casa L, Del Rio G, Glaser B, et al. Effect of 6-month gliclazide treatment on insulin release and sensitivity
to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin
infusion-induced normoglycemia. Am J Med. 1991;90(suppl 6A):37S-45S.
109. Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic
patients by transient intensive insulin treatment. Diabetes Care. 1997;20:1353-1356.
ABSTRACT
110. Glaser B, Leibovich G, Nesher R, et al. Improved beta-cell function after intensive insulin treatment in severe
non-insulin-dependent diabetes. Acta Endocrinol (Copenh). 1988;118:365-373.
111. Moura PV, Le Magoarou M, Paries J, et al. Short-term effects of continuous subcutaneous insulin infusion treatment
on insulin secretion in non–insulin-dependent overweight patients with
poor glycaemic control despite maximal oral anti-diabetic treatment. Diabete Metab. 1997;23:51-57.
ISI
| PUBMED
112. Kaplan RM, Wilson DK, Hartwell SL, et al. Prospective evaluation of HDL cholesterol changes after diet and physical
conditioning programs for patients with type II diabetes mellitus. Diabetes Care. 1985;8:343-348.
ABSTRACT
113. Lormeau B, Aurousseau MH, Valensi P, et al. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized
glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism. 1997;46:1074-1079.
FULL TEXT
|
ISI
| PUBMED
114. Jennings AM, Lewis KS, Murdoch S, et al. Randomized trial comparing continous subcutaneous insulin infusion
and conventional insulin therapy in type II diabetic patients poorly controlled
with sulfonylureas. Diabetes Care. 1991;14:738-744.
ABSTRACT
115. Saudek CD, Duckworth WC, Giobbie-Hurder A, et al. Implantable insulin pump vs multiple-dose insulin for non–insulin-dependent
diabetes mellitus. JAMA. 1996;276:1322-1327.
FREE FULL TEXT
116. Schmulling R-M, Jakober B, Pfohl M, et al. Exercise and insulin requirements. Horm Metab Res. 1990;24:83-87.
117. Mitchell TH, Abraham G, Schiffren A, et al. Hyperglycemia after intense exercise in IDDM subjects during continuous
subcutaneous insulin infusion. Diabetes Care. 1988;11:311-317.
ABSTRACT
118. Yki-Jarvinen H, DeFronzo RA, Koivisto VA. Normalization of insulin sensitivity in type I diabetic subjects by
physical training during insulin pump therapy. Diabetes Care. 1984;7:520-527.
ABSTRACT
119. Thuesen L, Christiansen JS, Sorensen KE, et al. Exercise capacity and cardiac function in type 1 diabetic patients
treated with continuous subcutaneous insulin infusion: a controlled study. Scand J Clin Lab Invest. 1986;46:779-784.
ISI
| PUBMED
120. Sachse G, Neuzner J, Maser E, et al. Continuous subcutaneous insulin infusion therapy (CSII) influences
cardiovascular responses to graded exercise in patients with autonomic diabetic
neuropathy of the cardiovascular system (ADNCS). Life Support Syst. 1985;3(suppl 1):530-534.
121. Chantelau E, Wirth R. Habitual physical activity in adult IDDM patients. Diabetes Care. 1992;15(suppl 4):1727-1731.
122. Jornsay DL, Duckles AE, Hankinson JP. Psychological considerations for patient selection and adjustment to
insulin pump therapy. 1988;14:291-296.
123. Holmes DM. The person and diabetes in psychosocial context. Diabetes Care. 1986;9:194-205.
ABSTRACT
124. Stein C. Psychological reactions to insulin infusion pumps. Med Clin North Am. 1982;66:1285-1292.
ISI
| PUBMED
125. Shapiro J, Wigg D, Charles MA, et al. Personality and family profiles of chronic insulin-dependent diabetic
patients using portable insulin infusion pump therapy: a preliminary investigation. Diabetes Care. 1984;7:137-142.
ABSTRACT
126. Wolf FM, Jacober SJ, Wolf LL, et al. Quality of life activities associated with adherence to insulin infusion
pump therapy in the treatment of insulin-dependent diabetes mellitus. J Clin Epidemiol. 1989;42:1129-1136.
FULL TEXT
|
ISI
| PUBMED
127. Grimm JJ, Haardt MJ, Thibult N, et al. Lifestyle, metabolic control and social implications of pump therapy
in 54 routine type 1 diabetic patients. Diabete Metab. 1987;13:3-11.
ISI
| PUBMED
128. Rudolf MC, Ahern JA, Genel M, et al. Optimal insulin delivery in adolescents with diabetes: impact of intensive
treatment on psychological adjustment. Diabetes Care. 1982;5(suppl 1):53-57.
129. Goldson D, Stewart J, Obrosky DS, et al. Psychological functioning of children with insulin-dependent diabetes
mellitus: a longitudinal study. J Pediatr Psychol. 1990;15:619-632.
FREE FULL TEXT
130. Walsh J, Roberts R. Pumping Insulin. San Diego, Calif: Torrey Pines Press; 1994.
131. Strowig SM. Initiation and management of insulin pump therapy. Diabetes Educ. 1993;19:50-59.
132. Norby D. Intensive Insulin Therapy Using an Insulin Infusion
Pump: A Guide to Developing a Protocol to Implement Insulin Pump Therapy. Minneapolis, Minn: Disetronic Medical Systems Inc; 1995.
133. Fredrickson I, ed. The Insulin Pump Therapy Book: Insights From the
Experts. Sylmar, Calif: MiniMed Technologies; 1995.
134. Boland E. Teens Pumping It! Insulin Pump Therapy Guide for
Adolescents. Sylmar, Calif: MiniMed Technologies; 1995.
135. Brink SJ, Stewart C. Insulin pump treatment in children, adolescents, and young adults. JAMA. 1986;255:617-621.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(19):2388-2389.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Insulin Pump Therapy: Guidelines for Successful Outcomes
Scheiner et al.
The Diabetes Educator 2009;35:29S-41S.
ABSTRACT
| FULL TEXT
Unexplained Hyperglycemia in Continuous Subcutaneous Insulin Infusion: Evaluation and Treatment
Ponder et al.
The Diabetes Educator 2008;34:327-333.
ABSTRACT
| FULL TEXT
The Experiences of School Nurses Caring for Students Receiving Continuous Subcutaneous Insulin Infusion Therapy
Darby
The Journal of School Nursing 2006;22:336-344.
ABSTRACT
| FULL TEXT
Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.
Nimri et al.
Pediatrics 2006;117:2126-2131.
ABSTRACT
| FULL TEXT
Insulin Pumps: What Every School Nurse Needs to Know
Cooper et al.
The Journal of School Nursing 2004;20:117-123.
ABSTRACT
| FULL TEXT
Continuous Subcutaneous Insulin Infusion
Diabetes Care 2004;27:s110-110.
FULL TEXT
Insulin pumps
Torrance et al.
Arch. Dis. Child. 2003;88:949-953.
FULL TEXT
Safety and Effectiveness of Insulin Pump Therapy in Children and Adolescents With Type 1 Diabetes
Plotnick et al.
Diabetes Care 2003;26:1142-1146.
ABSTRACT
| FULL TEXT
Nutrient Intake, Glycemic Control, and Body Mass Index in Adolescents Using Continuous Subcutaneous Insulin Infusion and Those Using Traditional Insulin Therapy
Wilson and Smith
The Diabetes Educator 2003;29:230-238.
Continuous Subcutaneous Insulin Infusion
Diabetes Care 2003;26:s125-125.
FULL TEXT
|
